Connect with us

Top Stories

EU agrees common purchase of vaccine, antiviral against monkeypox, paper

EU agrees common purchase of vaccine, antiviral against monkeypox, paper 1

STOCKHOLM (Reuters) – The European Union has decided on common purchasing of a vaccine and antiviral to fight the outbreak of monkeypox, a virus endemic in Africa and usually rare in other places, Sweden’s vaccine coordinator said on Friday.

“After several meetings it has been decided that we will buy both vaccine and an antiviral treatment,” Swedish daily Dagens Nyheter quoted coordinator Richard Bergstrom as saying.

The paper said the EU would buy Bavarian Nordic’s Imvanex and Tecovirimat from Siga Technologies in the United States.

Bergstrom said that the EU had not yet signed a contract with either firm.

“But it will go quickly. We should have a contract ready in a week or so and maybe some limited deliveries in June,” the paper quoted him saying.

Reuters was seeking comment from the EU on the report.

Imvanex is a vaccine against smallpox, to which monkey pox is closely related.

It has U.S. approval for the prevention of both smallpox and monkeypox. European Union approval is for smallpox, although doctors can prescribe it off-label for monkeypox.

Global health officials have tracked more than 200 suspected and confirmed cases of the usually mild viral infection in 19 countries since early May. The monkeypox variant implicated in the current outbreak has a case fatality rate of around 1%, though no deaths have been reported so far.

(Reporting by Simon Johnson; Editing by Angus MacSwan)

Editorial & Advertiser disclosure
Our website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
Global Banking and Finance Review Awards Nominations 2022
2022 Awards now open. Click Here to Nominate

Advertisement

Newsletters with Secrets & Analysis. Subscribe Now